Meeting
2022 ASCO Annual Meeting
Predictors of severe CRS in longitudinal CAR T-cell clinical trial data.
Authors
Caleb Strait
Acorn AI at Medidata, A Dassaults Systems company, New York, NY
Caleb Strait , Jacob Aptekar , Michael W. Kattan , Vibhu Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2540)
DOI
10.1200/JCO.2022.40.16_suppl.2540
Abstract #
2540
Poster Bd #
195
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.
First Author: Danielle Kirkey
Poster
2023 ASCO Annual Meeting
Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.
First Author: Jason Blair Litten
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson
Poster
2022 ASCO Annual Meeting
Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.
First Author: Xiuxiu Yang